Published in Future Oncol on June 22, 2016
Applications of molecular testing in surgical pathology of the head and neck. Mod Pathol (2017) 0.75
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer (2014) 40.30
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med (2008) 11.86
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature (2015) 5.50
Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res (1996) 4.89
The Genetic Evolution of Melanoma from Precursor Lesions. N Engl J Med (2015) 4.24
Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med (1990) 3.69
Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants. JAMA (2015) 3.62
Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science (2015) 3.29
Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol (2008) 3.16
Loss of heterozygosity (LOH) profiles--validated risk predictors for progression to oral cancer. Cancer Prev Res (Phila) (2012) 3.03
Oral epithelial dysplasia classification systems: predictive value, utility, weaknesses and scope for improvement. J Oral Pathol Med (2008) 2.82
Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res (2000) 2.71
Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov (2013) 2.49
Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res (2000) 2.34
Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol (2012) 2.34
Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med (1996) 2.29
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med (1993) 2.10
13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med (1986) 1.90
Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila) (2010) 1.80
3p14 and 9p21 loss is a simple tool for predicting second oral malignancy at previously treated oral cancer sites. Cancer Res (2002) 1.75
Increasing incidence of oral tongue squamous cell carcinoma in young white women, age 18 to 44 years. J Clin Oncol (2011) 1.68
Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals new recurrently-mutated genes and molecular subgroups. Nat Commun (2013) 1.62
Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. Clin Cancer Res (2001) 1.60
Notch1 mutations are drivers of oral tumorigenesis. Cancer Prev Res (Phila) (2014) 1.58
Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. JAMA Oncol (2016) 1.51
Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prev Res (Phila) (2013) 1.50
Sensitivity and specificity of OraScan (R) toluidine blue mouthrinse in the detection of oral cancer and precancer. J Oral Pathol Med (1996) 1.38
Molecular targets for cancer chemoprevention. Nat Rev Drug Discov (2009) 1.38
Why oral histopathology suffers inter-observer variability on grading oral epithelial dysplasia: an attempt to understand the sources of variation. Oral Oncol (2006) 1.25
Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol (2008) 1.25
Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res (2008) 1.23
Cessation of alcohol drinking, tobacco smoking and the reversal of head and neck cancer risk. Int J Epidemiol (2009) 1.22
A surprising cross-species conservation in the genomic landscape of mouse and human oral cancer identifies a transcriptional signature predicting metastatic disease. Clin Cancer Res (2014) 1.20
Gene expression profiling predicts the development of oral cancer. Cancer Prev Res (Phila) (2011) 1.13
A transcriptional progression model for head and neck cancer. Clin Cancer Res (2003) 1.06
Multiple pathways in the FGF signaling network are frequently deregulated by gene amplification in oral dysplasias. Int J Cancer (2009) 1.02
Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J Natl Cancer Inst (2003) 1.00
The Case for a Pre-Cancer Genome Atlas (PCGA). Cancer Prev Res (Phila) (2016) 0.91
Increased polysomies of chromosomes 7 and 17 during head and neck multistage tumorigenesis. Cancer Res (1993) 0.90
Precision cancer mouse models through genome editing with CRISPR-Cas9. Genome Med (2015) 0.89
Urinary PGE-M levels are associated with risk of colorectal adenomas and chemopreventive response to anti-inflammatory drugs. Cancer Prev Res (Phila) (2014) 0.88
Oral premalignant lesions: any progress with systemic therapies? Curr Opin Oncol (2012) 0.87
Two stem cell markers, ATP-binding cassette, G2 subfamily (ABCG2) and BMI-1, predict the transformation of oral leukoplakia to cancer: a long-term follow-up study. Cancer (2011) 0.87
The opposing roles of NOTCH signalling in head and neck cancer: a mini review. Oral Dis (2015) 0.86
MicroRNA expression profiling and functional annotation analysis of their targets associated with the malignant transformation of oral leukoplakia. Gene (2015) 0.81
Leukoplakia, Oral Cavity Cancer Risk, and Cancer Survival in the U.S. Elderly. Cancer Prev Res (Phila) (2015) 0.81
Field effect in oral precancer as assessed by DNA flow cytometry and array-CGH. J Oral Pathol Med (2011) 0.79
Gain of hTERC: a genetic marker of malignancy in oral potentially malignant lesions. Hum Pathol (2015) 0.78
New DNA Methylation Markers and Global DNA Hypomethylation Are Associated with Oral Cancer Development. Cancer Prev Res (Phila) (2015) 0.78
Animal models of head and neck squamous cell carcinoma. Vet J (2015) 0.76